Menu
Search
|

Menu

Close
X

Sellas Life Sciences Group Inc SLS.OQ (NASDAQ Stock Exchange Capital Market)

5.27 USD
-- (--)
As of Feb 22
chart
Previous Close 5.27
Open --
Volume --
3m Avg Volume 4,090
Today’s High --
Today’s Low --
52 Week High 24.21
52 Week Low 5.07
Shares Outstanding (mil) 5.77
Market Capitalization (mil) 30.39
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
3
EPS (USD)
FY17
-13.021
FY16
-34.640
FY15
-158.422
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
0.50
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
83.15
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-67.51
13.67
Return on Equity (TTM)
vs sector
-90.82
15.40

EXECUTIVE LEADERSHIP

Angelos Stergiou
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Aleksey Krylov
Interim Chief Financial Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Nicholas Sarlis
Chief Medical Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Gregory Torre
Chief Regulatory Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
John Burns
Vice President - Finance, Corporate Controller, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

315 Madison Ave Frnt 4
NEW YORK   NY   10017-5405

Phone: +1813.8644523

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.

SPONSORED STORIES